The Medicines Patent Pool has signed a license agreement with the University of Washington for a long-acting injectable drug combination candidate being developed for use as an HIV treatment. The project is being supported by MPP’s founder Unitaid through its Global Long-Acting Drug project.
The license incorporates the “patents and expertise” relating to the candidate, which aims to transform the World Health Organization recommended daily oral dosage of TLD (tenofovir/lamivudine/dolutegravir) into a monthly subcutaneous injection